Efficacy Assessment of the High-Frequency High-Intensity Focused Ultrasound as a New Treatment for Actinic Keratosis.


Journal

Dermatology (Basel, Switzerland)
ISSN: 1421-9832
Titre abrégé: Dermatology
Pays: Switzerland
ID NLM: 9203244

Informations de publication

Date de publication:
2022
Historique:
received: 10 06 2021
accepted: 28 10 2021
pubmed: 22 12 2021
medline: 9 7 2022
entrez: 21 12 2021
Statut: ppublish

Résumé

Actinic keratosis (AK) is the most common precancerous cutaneous lesion, with risk of progression to cutaneous squamous cell carcinoma. In the current study, we evaluated the efficacy of 20-MHz high-intensity focused ultrasound (HIFU), as a new treatment modality for AK. Patients with AK lesions (grades I-III) treated with HIFU were included in the study. The clinical assessment was performed 3 months after therapy. Twenty-one patients (14 men, 7 women) with 108 AK lesions (grades I-III) were included in the current study. Ages ranged from 62 to 85 years (mean 72.6 years). Clinically complete resolution of the actinic damage in the treated area was detected in 72.2% of lesions. Furthermore, 28 lesions (26%) showed a reduction of the AK grade, or partial response, after the therapy. Most of the patients experienced annoying but short pain during the procedure. However, late adverse effects of the therapy, such as hypopigmentation, hyperpigmentation and erythema were reported only in a small portion of the lesions. 20-MHz HIFU could be an effective and safe alternative treatment for AK.

Sections du résumé

BACKGROUND BACKGROUND
Actinic keratosis (AK) is the most common precancerous cutaneous lesion, with risk of progression to cutaneous squamous cell carcinoma. In the current study, we evaluated the efficacy of 20-MHz high-intensity focused ultrasound (HIFU), as a new treatment modality for AK.
MATERIALS AND METHODS METHODS
Patients with AK lesions (grades I-III) treated with HIFU were included in the study. The clinical assessment was performed 3 months after therapy.
RESULTS RESULTS
Twenty-one patients (14 men, 7 women) with 108 AK lesions (grades I-III) were included in the current study. Ages ranged from 62 to 85 years (mean 72.6 years). Clinically complete resolution of the actinic damage in the treated area was detected in 72.2% of lesions. Furthermore, 28 lesions (26%) showed a reduction of the AK grade, or partial response, after the therapy. Most of the patients experienced annoying but short pain during the procedure. However, late adverse effects of the therapy, such as hypopigmentation, hyperpigmentation and erythema were reported only in a small portion of the lesions.
CONCLUSIONS CONCLUSIONS
20-MHz HIFU could be an effective and safe alternative treatment for AK.

Identifiants

pubmed: 34933303
pii: 000520536
doi: 10.1159/000520536
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

662-667

Informations de copyright

© 2021 S. Karger AG, Basel.

Auteurs

S Morteza Seyed Jafari (SM)

Department of Dermatology, Inselspital, Bern University Hospital, Bern, Switzerland.

Simone Cazzaniga (S)

Department of Dermatology, Inselspital, Bern University Hospital, Bern, Switzerland.

Simon Bossart (S)

Department of Dermatology, Inselspital, Bern University Hospital, Bern, Switzerland.

Laurence Feldmeyer (L)

Department of Dermatology, Inselspital, Bern University Hospital, Bern, Switzerland.

Lorenzo Pelloni (L)

Department of Dermatology, Inselspital, Bern University Hospital, Bern, Switzerland.

Maja van Rhyn (M)

Department of Dermatology, Inselspital, Bern University Hospital, Bern, Switzerland.

Sarina Angermeier (S)

Department of Dermatology, Inselspital, Bern University Hospital, Bern, Switzerland.

Maurice Adatto (M)

Department of Dermatology, Inselspital, Bern University Hospital, Bern, Switzerland.

Robert E Hunger (RE)

Department of Dermatology, Inselspital, Bern University Hospital, Bern, Switzerland.

Kristine Heidemeyer (K)

Department of Dermatology, Inselspital, Bern University Hospital, Bern, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH